Tesamorelin
Read the full narrative Deep Dive on Tesamorelin →
A synthetic analogue of growth hormone-releasing hormone (GHRH), administered by daily subcutaneous injection.
Developed specifically to address excess visceral abdominal fat (lipodystrophy) in people living with HIV, a recognised complication of HIV and its treatment.
FDA-approved in the United States for this single, specific indication since 2010. Not authorised by the MHRA (UK) or EMA (EU) for any indication.
Why this profile sits at a different evidence level than most others in this library
Tesamorelin is one of the few compounds discussed in this space with genuine Phase III randomised controlled trial data and a real regulatory approval behind it. That approval is narrow: one country, one specific patient population, one specific outcome measure. It is not a general endorsement of tesamorelin for any other use, and it is explicitly not approved in the UK, where it has no marketing authorisation and no licensed medical use.
Proposed mechanism of action
Established
As a GHRH analogue, tesamorelin binds GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone. This mechanism is well-characterised and is the basis on which its approved effect on visceral fat was demonstrated in trials.
Proposed / not established for other uses
Broader claims about general fat loss, anti-ageing, or athletic performance extend beyond the mechanism actually tested in the approved indication, and are not supported by the trial evidence described below.
What's actually been published, by evidence level
Laboratory / In-vitro
Receptor-binding and endocrine pharmacology studies supporting the GHRH mechanism.
Animal / Preclinical
Preclinical pharmacology supporting growth-hormone-axis activity ahead of human trials.
Early Human Evidence
Early-phase human pharmacokinetic and dose-finding studies preceded the pivotal trials.
Controlled Human Evidence
Two randomised, double-blind, placebo-controlled Phase III trials (combined n=806) plus the original pivotal 412-patient RCT.
Established Clinical Evidence
FDA-approved (2010) for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy — this specific indication only. EMA marketing authorisation application was withdrawn (2012) after an unfavourable benefit-risk review. No UK/MHRA authorisation exists.
- Study type
- Randomized, double-blind, placebo-controlled, Phase III
- Population
- 412 HIV-infected adults with excess abdominal fat
- Main finding
- 15.2% reduction in visceral adipose tissue with tesamorelin 2mg subcutaneous daily vs. placebo
- Study type
- Pooled analysis, two randomized, double-blind, placebo-controlled Phase III trials
- Population
- 806 ART-treated adults with HIV-associated abdominal fat accumulation (tesamorelin n=543, placebo n=263)
- Design
- 26-week treatment period, 26-week safety extension
FDA approved tesamorelin (Egrifta) on 10 November 2010 for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy, based on the trials above. Ferrer Internacional's application for EU marketing authorisation (submitted 2011) was withdrawn in 2012 after the EMA's Committee for Medicinal Products for Human Use concluded the data did not support a positive benefit-risk balance. No MHRA marketing authorisation has been identified for the UK.
This label reflects real Phase III trial data and an actual regulatory approval — but only for one indication, in one jurisdiction. It is not a statement that tesamorelin is approved, authorised, or established as effective for any other use, or in the UK specifically, where it holds no licence.
What This Evidence Does NOT Establish
- FDA approval for HIV-associated lipodystrophy does not establish effectiveness for general fat loss, bodybuilding, or anti-ageing use — those are different claims the approved trials did not test.
- US approval does not mean tesamorelin is licensed or legal to supply as a medicine in the UK or EU — it explicitly is not.
- The EMA's withdrawal of its review does not prove tesamorelin is unsafe generally — it reflects a specific benefit-risk judgement for that application, in that population, at that time.
- A well-established mechanism (GHRH receptor stimulation) does not mean every downstream effect attributed to raising growth hormone is proven by these trials.
Where the Evidence Conflicts
The FDA and EMA reviewed substantially the same evidence base and reached different conclusions — the FDA approved it, the EMA's scientific committee did not consider the benefit-risk balance positive enough to approve it for the EU market. That's a genuine, documented regulatory disagreement about the same data, not a gap in the data itself — worth knowing before treating "FDA-approved" as the end of the conversation.
"Tesamorelin is an FDA-approved peptide, so it's a proven, safe way to boost growth hormone for fat loss or anti-ageing."
Real Phase III RCT data in 412 and a pooled 806 HIV-infected adults, showing a specific reduction in visceral abdominal fat in that population, leading to FDA approval for that single indication.
Tesamorelin has demonstrated, trial-backed efficacy for visceral fat reduction specifically in HIV-associated lipodystrophy. It has not been shown by this evidence to be effective or appropriately studied for general fat loss, anti-ageing, or performance use in a different population.
Whether the same effect, dosing, and safety profile would hold in people without HIV-associated lipodystrophy — a genuinely different population the pivotal trials did not study.